Rutgers New Jersey Medical School will be a clinical test site for a study assessing the long term risk of chronic kidney disease in patients who recover from COVID-19. The Multi-Center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID) study – conducted by the Division of Nephrology at Mount Sinai – will assess risk in up to 4,000 patients who have recovered from COVID-19 using the artificial-intelligence diagnostic system KidneyIntelX that can incorporate novel protein biomarkers and provide insight into the disease. Researchers will also study patients’ COVID-19 antibody levels over time, which will provide insights into the interaction between immune response and kidney-related complications. Initial research findings are expected to be reported in early 2021. To read the full story.